Department of Biochemistry, Faculty of Pharmacy, Tanta University, 31511, Egypt.
Department of Clinical Oncology, Faculty of Medicine, Tanta University, 31511, Egypt.
Life Sci. 2020 Oct 15;259:118193. doi: 10.1016/j.lfs.2020.118193. Epub 2020 Aug 5.
Circulating long non-coding RNAs (lncRNAs) have proven to be useful non-invasive tools for diagnosis of various cancers. FAM83H antisense RNA 1 (FAM83H-AS1) and lncRNA activated by TGF β (lncRNA-ATB) are two lncRNAs that have been shown to play an important role in different cancer types including breast cancer. The primary aim of our study was to investigate the potential role of serum FAM83H-AS1 and lncRNA-ATB as diagnostic/prognostic markers for breast cancer patients.
Serum expression levels of FAM83H-AS1 and lncRNA-ATB were analyzed in 90 breast cancer patients and 30 age- and sex-matched healthy controls using RT-qPCR.
We found that FAM83H-AS1 and lncRNA-ATB were significantly overexpressed in sera of breast cancer patients compared to controls (p = 0.000 for both). Analysis of receiver operating characteristic curve demonstrated that lncRNA-ATB had a higher area under curve (AUC) value than the conventional tumor marker cancer antigen 15-3 (CA15-3) (AUC: 0.844, p = 0.000 versus 0.738, p = 0.002) for early diagnosis of breast cancer in patients with stage I-II. On the other hand, FAM83H-AS1 showed a significant correlation with tumor-node metastasis (TNM) stages, large tumor size and lymph node metastasis, suggesting a prognostic rather than diagnostic value.
This is the first study to demonstrate that serum lncRNA-ATB could be used as a non-invasive diagnostic marker for early stages of breast cancer. Furthermore, serum FAM83H-AS1 has a potential ability for monitoring of progression and staging of breast cancer.
循环长非编码 RNA（lncRNA）已被证明是诊断各种癌症的有用非侵入性工具。FAM83H 反义 RNA 1（FAM83H-AS1）和 TGFβ 激活的长非编码 RNA（lncRNA-ATB）是两种 lncRNA，它们已被证明在包括乳腺癌在内的不同癌症类型中发挥重要作用。我们研究的主要目的是探讨血清 FAM83H-AS1 和 lncRNA-ATB 作为乳腺癌患者诊断/预后标志物的潜在作用。
使用 RT-qPCR 分析 90 例乳腺癌患者和 30 名年龄和性别匹配的健康对照者血清中 FAM83H-AS1 和 lncRNA-ATB 的表达水平。
与对照组相比，乳腺癌患者血清中 FAM83H-AS1 和 lncRNA-ATB 明显过表达（两者均 p=0.000）。接受者操作特征曲线分析表明，lncRNA-ATB 对 I 期和 II 期乳腺癌患者的早期诊断具有比传统肿瘤标志物癌抗原 15-3（CA15-3）更高的曲线下面积（AUC）值（AUC：0.844，p=0.000 与 0.738，p=0.002）。另一方面，FAM83H-AS1 与肿瘤-淋巴结-转移（TNM）分期、肿瘤较大和淋巴结转移显著相关，提示其具有预后而不是诊断价值。
这是首次研究表明，血清 lncRNA-ATB 可作为乳腺癌早期的非侵入性诊断标志物。此外，血清 FAM83H-AS1 具有监测乳腺癌进展和分期的潜在能力。
